Clinical trials: Aripiprazole
Bioequivalence
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
To compare the rate and extent of absorption of Aripiprazole Orally disintegrating tablets 10 mg of Chengdu Kanghong Pharmaceutical Group Co.,Ltd, China and ABILIFY (Aripiprazole) 10 mg orodispersible tablets of Otsuka…
- Trial name
- NCT03232710
- Testing
- Bosiqing, abilify
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
Bipolar I Disorder
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group-comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
The primary objective of this trial is to evaluate the clinical efficacy and safety of aripiprazole in comparison to placebo in patients with Bipolar I Disorder experiencing a manic or mixed episode.
- Trial name
- NCT00606281
- Testing
- Aripiprazole
- Where
- 12 sites in China, Japan and 2 more
- Volunteers
- 258 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia
The purpose of the trial was to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole as maintenance treatment in patients with schizophrenia.
- Trial name
- ASPIRE (NCT00705783)
- Testing
- Aripiprazole depot
- Where
- 110 sites in United States, Argentina and 10 more
- Volunteers
- 843 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Metabolic Syndrome X
An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics
The purpose of the study is to find and follow-up the metabolic syndrome parameters on patients administering atypical antipsychotics.
- Trial name
- MESSAGE (NCT00448630)
- Testing
- No intervention
- Where
- 47 sites in Turkey (Türkiye)
- Volunteers
- 328 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Tourette's Disorder
Efficacy & Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder (TD)
The goal of the current trial is to determine efficacy and safety of once-weekly aripiprazole in reducing Total Tic Severity (TTS) score in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01418352
- Testing
- Aripiprazole
- Where
- 35 sites in United States, Bulgaria and 3 more
- Volunteers
- 83 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode
The purpose of this study is to evaluate flexible doses (5-30mg) of aripiprazole versus placebo in patients with bipolar depression.
- Trial name
- NCT00080314
- Testing
- Aripiprazole
- Where
- 28 sites in United States
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Real Life Assessment of Abilify Maintena
This is a non-interventional, Canadian, study in patients treated with Abilify Maintena™ for schizophrenia followed for 24 months, with 9 visits recommended.
- Trial name
- ReLiAM (NCT02131415)
- Where
- 17 sites in Canada
- Volunteers
- 200 people
- Sponsor
- Lundbeck Canada Inc.
Bipolar Disorder
A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode
Efficacy of Aripiprazole in Combination with Lamotrigine in the Long-Term Maintenance Treatment of Bipolar I Disorder in Outpatients with Recent Manic or Mixed Episode
- Trial name
- NCT00277212
- Testing
- Lamotrigine + Aripiprazole
- Where
- 66 sites in United States, Puerto Rico
- Volunteers
- 1,169 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia
- Trial name
- NCT03150771
- Testing
- Aripiprazole
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar Disorder
Study of Aripiprazole in Patients With a History of Bipolar Disorder
The purpose of this study is to learn if aripiprazole is effective in the treatment of patients with a history of bipolar disorder.
- Trial name
- NCT00036348
- Testing
- Aripiprazole
- Where
- 19 sites in United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Tourette's Disorder, Tic Disorder
Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder
The goal of the current trial is to determine safety of Once-daily aripiprazole in reducing Total Tic Severity in children and adolescents with Tourette's Disorder.
- Trial name
- NCT01727713
- Testing
- Aripiprazole
- Where
- 33 sites in United States, Canada and 2 more
- Volunteers
- 110 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients
The purpose of this study is to evaluate the effect on patient weight of adjunctive therapy of aripiprazole with clozapine versus clozapine monotherapy, in schizophrenic patients who are not optimally controlled on clozapine.
- Trial name
- NCT00300846
- Testing
- aripiprazole
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 200 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Bipolar Affective Disorder
Quality of Life, Safety and Compliance of Patients Using Monotherapy or Combinatorial Therapy With Quetiapine for Treatment of Schizophrenia or Bipolar Affective Disorder
The goal of this observational study is to evaluate the quality of life, drug safety and therapy compliance of schizophrenia or bipolar affective disorder patients during the treatment with quetiapine monotherapy or in…
- Trial name
- NCT07858565
- Testing
- Quetiapine (drug), quetiapine + aripiprazole, quetiapine + haloperidol
- Where
- Bosnia and Herzegovina
- Volunteers
- 500 people
- Sponsor
- Bosnalijek D.D
Chronic Motor or Vocal Tic Disorder, Tourette's Disorder
Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder
The purpose of this trial is to demonstrate the efficacy and safety of aripiprazole in children and adolescents aged 6~18 years with chronic tic disorders or Tourette's disorder
- Trial name
- NCT00706589
- Testing
- aripiprazole
- Where
- 6 sites in South Korea
- Volunteers
- 61 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.
- Trial name
- NCT00239356
- Testing
- Aripiprazole
- Where
- 20 sites in Canada, Croatia and 9 more
- Volunteers
- 119 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Schizoaffective Disorder
A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices
The purpose of this clinical research study is to evaluate the overall effectiveness of 8 week of aripiprazole treatment.
- Trial name
- NCT00292409
- Testing
- Aripiprazole
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms
The purpose of this study is to determine whether LY2140023, when added to standard-of-care antipsychotic treatment, will improve negative symptoms.
- Trial name
- NCT01052103
- Testing
- LY2140023, Standard of Care
- Where
- 9 sites in United States, Israel and 2 more
- Volunteers
- 167 people
- Sponsor
- Denovo Biopharma LLC
Psychotic Disorders, Schizophrenia
Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants
The purpose of this study is to gather information about the steady-state plasma concentrations of aripiprazole, olanzapine, quetiapine and their relevant metabolites, at various dose levels and at different time points after…
- Conditions
- Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
- Trial name
- NCT02087579
- Testing
- Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation
- Where
- 24 sites in United States, Argentina and 5 more
- Volunteers
- 305 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia
The primary objective of this study was to continue to provide aripiprazole intramuscular (IM) depot treatment (400 milligrams [mg] or 300 mg) to participants with schizophrenia completing the 52-week, open-label safety and…
- Trial name
- ASPIRE (NCT01129882)
- Testing
- Aripiprazole
- Where
- 157 sites in United States, Argentina and 22 more
- Volunteers
- 709 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia, Alzheimer Type
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
The primary objective of the study is to compare the efficacy of aripiprazole with placebo in patients with psychosis associated with Alzheimer's dementia.
- Trial name
- NCT01438060
- Testing
- Aripiprazole (BMS-337039)
- Volunteers
- 232 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.